Cashing in on Coronavirus: Biopharma NanoViricides sees stock soar on coronavirus claims

As the coronavirus was spreading in China, a small biopharma company, NanoViricides, claimed it was close to clinical trials for a treatment. A CNBC investigation found the 15-year-old company has never tested a product in humans and never made a penny in revenue. Andrea Day reports.